Board & Executives

Mr. David Goren, Chief Executive Officer, Chairman of the Board, Director

MBA, Columbia University

D.Goren vaxil

David is a seasoned pharma executive with extensive experience in strategy, establishing new life science businesses, and most recently specializing in digital health. David has held various executive commercial and corporate positions in the pharmaceutical industry since 1991. David is currently a strategy consultant to pharma and start-up companies with a focus in life sciences and digital. He also serves as board member of 2 early-stage pharma companies in the oncology and Alzheimer’s therapeutic areas, and provides mentoring and coaching to a variety of executives in healthcare and beyond.

He recently left AstraZeneca (after 10 years) as VP Digital Health Strategy. David established AstraZeneca Israel in 2007, and served as Company President until 2014, when he led the global HR Transformation program. Prior to that, in 2011, David led AstraZeneca’s global initiative to revise the policy for ethical interactions with customers and partners.

In 1997, David created Pfizer’s Israel operation and became the CEO and General Manager of Pfizer Israel. David returned to Pfizer US Headquarters in 2004 to lead the Worldwide Strategy and Business Development Group. Prior to being in Israel, David served in various senior sales and marketing roles.

David has an MBA from Columbia University, a Bachelors in Biology from Clark University, and has attended Harvard, MIT and INSEAD Executive Management Programs.

David has served on various boards including the Raanana Symphonette Orchestra, Kids Kicking Cancer and the Business Ethics Center of Jerusalem.

Dr. Ari S. Kellen, M.D., Director

Medical Doctor, University of Witwatersrand | MBA, University of Witwatersrand

Dr. Ari S. Kellen MD Vaxil

Dr. Ari Kellen is an experienced senior executive with over three decades of healthcare industry experience. After practicing medicine and running a large segment of the Johannesburg Hospital in South Africa, Dr. Kellen was recruited to McKinsey & Company where he spent 22 years as a strategic advisor to boards of directors and CEOs of major health care clients across the globe.

In 2014 Dr. Kellen was recruited to Valeant Pharmaceuticals. Running US Bausch + Lomb, R&D, Latin America and Dermatology, he helped lead the company through a challenging period involving a change in leadership and business strategy, and was subsequently promoted by the new CEO and Board to the global segment leader of Bausch + Lomb.

Since 2017 Dr. Kellen has been serving as a strategic advisor and investor to early-stage innovative healthcare companies in the US, Europe, and Israel. He serves on the boards of Theraclion and Vaxil Bio, and is a strategic advisor to several other companies including BioNanoSim and Nouri Life. Dr Kellen is a graduate of the University of the Witwatersrand in South Africa where he received his Medical and MBA degrees with distinction.

Dr. Shawn Langer, M.D., Director

Medical Doctor, University of Toronto

Dr. Shawn Langer MD Vaxil

Dr. Shawn Langer brings over two decades of healthcare industry experience. Dr. Langer was Senior Partner at McKinsey & Company, where he was the leader of its Healthcare Private Equity Group.

During his 15 years with McKinsey & Company, Dr. Langer served healthcare clients across pharmaceuticals, biotechnology, medical devices, and healthcare services.

Most recently Dr. Langer has spent nearly 5 years investing in innovative healthcare companies in his capacity as a portfolio manager at healthcare private equity investment firm BMHS Investments.

Dr. Langer holds an MD from the University of Toronto.

Mr. Gadi Levin, C.A. B.Comm, CFO & Director

Masters of Science (MSc) in Accounting and B.Commerce | Chartered Accountant | MBA


Mr. Levin is an accountant with clinical-stage biotech experience. Mr. Levin served as Chief Financial Officer of Labstyle Innovations Ltd, a biotechnology company focused on diabetes. Mr. Levin served as the Vice President of Finance and Chief Financial Officer for two Israeli investment houses in the fields of private equity, hedge funds and real estate. More recently, Mr. Levin served as Chief Financial Officer of BriaCell Therapeutics Corp. developing an immunotherapy for late stage cancer patients.
Mr. Levin began his career at the former “Big Five” accounting firm Arthur Andersen, where he worked in the Cape Town, London, and Tel Aviv offices for nearly ten years. He holds a Bachelor of Commerce degree in Accounting and Information Systems from the University of the Cape Town, South Africa, and a Post-Grad in Accounting from the University of South Africa. He received his Chartered Accountant designation in South Africa and has an MBA from Bar Ilan University in Israel.